Becton, Dickinson & Company to demerge its Biosciences and Diagnostic Solutions business.

Becton, Dickinson & Company, a global medical technology company, is set to demerge its Biosciences and Diagnostic Solutions business. "We believe the separation will position New BD as a differentiated MedTech leader and enable optimized investment to accelerate our innovation pipeline and ongoing margin enhancement through BD Excellence to further fund growth. We believe Biosciences and Diagnostic Solutions is expected to deliver substantial value as a pure-play leader in life sciences and will be well-positioned to execute on its unique and compelling solutions and growth opportunities. This transaction is designed to position both businesses to thrive in our respective sectors and deliver value for shareholders," Tom Polen, BD Chairman, CEO and President.